Business
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channelsHighlightsUses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperatureDesigned for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative...
About this update from Tempramed Technologies Ltd.
[{"type":"text","content":"Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channels","length":200,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature","length":171,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Expanded portfolio to pursue larger and more diversified revenue opportunities, including: patients using high-cost biologics and GLP-1 therapies, Healthcare providers and specialty pharmacies, and B2B partners seeking standardized medication-protection solutions","length":263,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Substantially increases the scope of commercial reach and addressable market opportunity","length":88,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":718,"olType":false},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - January 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the commercial launch of VIVI Med™, a new temperature-protection solution designed to safeguard medication vials, biologics, and other critical therapies that fall outside the insulin-pen format.","length":487,"tagName":"p"},{"type":"text","content":"The launch of VIVI Med™ provides significant expansion of the Company's total addressable market opportunity, by extending its proven thermal-protection technology into new drug categories, broader patient populations, and higher-value use cases. By addressing medications such as GLP-1 receptor agonists, biologics including Humi...